The BBS and EFSPI planned to hold a one day HTA seminar on June 30 at Novartis, but due to the current COVID-19 situation, the organizers have decided to hold it this year as a shortened 2-hour webinar on the same date which is free to attend.
Flyer and full details on how to register
********
Disclaimer: All comments which were made during the Webinar are from the speakers themselves, and do not necessarily represent the position of the companies and organizations which they represent.
Link to panel discussion recording
Chrissie Fletcher, GSK UK Celebrating 10 Years HTA SIG
Christoph Schürmann, IQWiG, Germany Health-related quality of life endpoints in benefit assessments: Demands and challenges as seen by IQWiG in Germany
Lara Wolfson, Merck USA Issues related to transparency with HTA dossiers
Mark Nuijten, A2M and Univ. of Maastricht, NL & ITU, Turkey An innovative pricing model to assess the price of expensive drugs with an orphan indication
Fred Sorenson, Xcenda, member of BBS board Introduction to moderated panel discussion
Final announcement & program Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology?
Date: Monday, 29th June 2020, 09:00-11:45
Webinar: dial-in details will be communicated to registered participants
After the publication of the final version of the ICH E9 addendum, the BBS jointly with EFSPI would like to offer a half-day webinar on the broad topic of estimands in oncology drug development.
The event will feature talks from statisticians and clinicians in industry, regulatory agencies, and academia.
Initially, this event was planned as a full-day seminar on the Novartis campus. Given the current COVID-19 situation we turn this event into a series of webinars.
If you’d like to attend please fill out the registration form. After registration you will receive a calendar invite with a webex link.
The webinar is free of charge.
The organizing committee members are Evgeny Degtyarev, Kaspar Rufibach, Bibiana Blatna, Marie- Laure Casadebaig, Lynda Grinsted, Lorenzo Guizzaro, Wolfgang Kothny, Giusi Moffa, Hans-Jochen Weber. The event is supported by the European special interest group “Estimands in oncology”, sponsored by PSI and EFSPI, which is also an ASA scientific working group: http://www.oncoestimand.org.
********
Link to recording
Questions from the webinar chat addressed by the members of the organizing committee and panelists
Kaspar Rufibach, Roche, member of BBS board Welcome and scene setting
Anja Schiel, Norwegian Medicines Agency Experience with the estimand framework in oncology
Renaud Capdeville, Novartis Challenges and open questions in hematology: RATIFY
Tina Nielsen, Roche Challenges and open questions in hematology: GALLIUM
Hannes Buchner, Staburo & Ingolf Griebsch, Boehringer Ingelheim Treatment switching: challenges, estimands, and estimators
Stefan Englert, AbbVie Commentary on previous talks taking COVID-19 into account
Final Announcement BBS Seminar Network meta-analysis: methods and applications
The BBS is pleased to host a half-day seminar on network meta-analysis methods and applications.
The talks will present recent methodological advances and challenges as well as case studies from
the pharmaceutical industry and academia. We welcome all quantitative scientists to this event, which
will be a great opportunity to meet with colleagues and exchange ideas on this emerging and vibrant
field.
The seminar is free of charge but registration is mandatory for organizational reasons. Please register
via email to fred.sorenson@xcenda.com by Tuesday, January 21st, 2020, the latest.
The seminar takes place on February 4th, 2020 from 13:00-17:30
Venue: Roche Auditorium Building 92, Grenzacherstrasse 124, 4070 Basel
Sylwia Bujkiewicz, Bivariate network meta-analysis for surrogate endpoint evaluation
Gerta Rücker, Component network meta-analysis compared to a matching method in a disconnected network: a case study
Georgia Salanti, CINeMA: a framework and web application to evaluate the confidence in network meta-analysis results
Mark Pletscher, Network meta-analysis of treatments for previously untreated
metastatic PD-L1-positive triple-negative breast cancer
Bartosz Jenner, An experience with indirect treatment comparisons using MAIC methods in a rare disease (slide deck not available)
Marius Thomas, A network meta-analysis to compare efficacy of treatment options for relapsing-remitting multiple sclerosis
Check out the event dedicated page for a summary of the day.
The BBS is pleased to host a full-day seminar on predictive modelling, machine learning, and causality with several eminent speakers. The talks will present recent methodological advances and challenges as well as case studies from the pharmaceutical industry and academia. We welcome all quantitative scientists to this event which will be a great opportunity to meet with colleagues and exchange ideas on this emerging and vibrant field.
The seminar is free of charge but registration is mandatory for organizational reasons. Please register via email to fred.sorenson@xcenda.com by Friday, October 18, 2019, the latest.
Date: Friday, November 1st, 2019, 08:30-16:45
Venue: Auditorium Roche Builing 683, Viaduktstrasse 31-35, Basel
Full program in pdf – with abstracts
Meeting agenda in pdf
Slide decks
Ewout Steyerberg, Clinical prediction models in the age of artificial intelligence and big data
Willi Sauerbrei, The EQUATOR networkand guidelines for prediction models
Torsten Hothorn, Score-based transformation learning
Peter Bühlmann, Causal regularization for distributional robustness and replicability
Giusi Moffa, Predicting putative intervention effects after causal structure learning from survey data
Andrew Shattock, Using machine learning and disease models to evaluate target product profiles of novel interventions (No slide deck available)
FedericoMattiello, Identifying high-risk patients in Non-Hodgkin lymphoma (and trying to get insights into the disease biology)
Mark Baillie, Novartis benchmarking initiative: making sense of AI
Chris Harbron, Experiences from running internal prediction challenges within a pharmaceutical company
August 21, 2019 from 9:00 – 16:00
Location: Roche, Building 001, Auditorium 2nd Floor
This Seminar is free of charge.
Please register via the BES homepage
Registration closes on August 9, 2019
Agenda
Date: August 19-20, 2019
Time: 9:00 – 17:00
Location: Roche Auditorium, Building 001, Auditorium 2nd Floor Fee: Industry: CHF 200 / Academia: CHF 100 / Students: 10 seats available free of charge
Registration: By e-mail to fred.sorenson@xcenda.com
Flyer
Final announcement
Precision medicine aims to tailor disease prevention, diagnosis and treatment to the individual patient, based on their individual features extracted from multiple types of data (such as multi-omics, imaging, patient history, lifestyle and environmental factors).
Advances in screening platforms and the availability of big data are fueling the scientific progress in precision medicine, spanning the early stage of drug discovery all the way through translation into clinical practice. Adequate use of statistical and computational methods are critical to its successful implementation in clinics.
The Basel Biometric Section (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a European scientific meeting on this relevant and far-reaching topic. The purpose is to bring together experts from the pharmaceutical industry, academia and the European regulatory bodies to present the current state of the art and discuss the challenges and opportunities ahead.
The seminar takes place on June 4, 2019 from 9:00-17:00
Venue: Actelion Pharmaceuticals, Hegenheimermattweg 95, Allschwil, Switzerland
TO REGISTER PLEASE GO TO: www.efspi.org
Presentations
Niko Beerenwinkel, Bioinformatics for precision oncology (slide deck not available)
Stephen Senn, Precision medicine: The honeymoon is over. It’s high time for tough love
Tomasz Burzykowski, Generalized pairwise comparisons for precision medicine
Adam Heathfield, Valuation of Regenerative Medicine/Advance Therapeutics (RM/ATs): Challenges and opportunities for creating a better framework
JackKuipers, Mutational interactions define novel cancer subgroups: can they inform precision oncology?
Mario Ouwens, Difficulties with network meta-analysis when starting to use PDL1 thresholds
Georgina Bermann, Cardiovascular medicine: approaches to the use of early biomarker response to identify a patient subgroup with enhanced therapeutic benefit
Laurent Essioux, Examples of personalized Healthcare at Roche: statistical perspectives
Final Announcement BBS Spring Seminar Synthetic controls – what do we need and how far can we go?
The seminar takes place on May 10, 2019 from 9:00-16:30
Venue: Roche Auditorium, Viaduktstrasse, Basel
The seminar is free of charge. For organizational reasons please register by sending an email in advance to fred.sorenson@xcenda.com
Registration will close by Friday, April 26, 2019
Tom Brookland, RWD/RWE Global Regulatory Overview
Kaspar Rufibach and Hans Ulrich Burger, External controls in drug development
Somnath Sarkar, Considerations for Developing External Control Arm from Real-World Data
Laurence Colin and Yue Li, Making better use of early phase safety data
Cornelia Dunger-Baldauf, For the sake of the patient – reducing placebo exposure by using historical controls
Gonzalo Duran-Pacheco, Electronic Health Records used to derive Control Arms for Single-Arm oncology trials: Proof of concept using RCT’s in lung cancer
Chris Harbron, A Decision Making Framework For Utilising External Control Arms
Meinhard Kieser, Synthetic controls – what do we need and how far can we go? Rejoinder
Norbert Benda, Synthetic controls – what do we need and how far can we go? Rejoinder
Kit Roes, Synthetic controls – what do we need and how far can we go? Rejoinder
Jan Müller-Berghaus, Synthetic controls – what do we need and how far can we go? Rejoinder
(no slide deck available)
Anja Schiel, Synthetic controls – what do we need and how far can we go? Rejoinder
(no slide deck available)
